Sean Nolan, RA Session II

Crossover round? Check. Top team? Check. Taysha sails to an IPO with $100M ini­tial ask

On the same day No­var­tis erased the AveX­is brand from the com­pa­ny, the ex-AveX­is crew says their new gene ther­a­py start­up is ready for an IPO.

Taysha Gene Ther­a­pies has left enough bread crumbs for biotech sleuths to fig­ure out that it’s go­ing down this path. CEO RA Ses­sion II, who hap­pi­ly chat­ted to mul­ti­ple re­porters at launch, de­clined in­ter­views for the re­cent Se­ries B (and pre­sumed crossover round); the biotech brought in a gene ther­a­py pro­gram de­vel­oped by its co-founder Steven Gray from Abeona; and days ago it tapped the ex-CMO and ex-CFO of AveX­is to join the board, chaired by their for­mer boss Sean Nolan.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.